^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CRKL amplification

    i
    Other names: CRKL, CRK Like Proto-Oncogene, Adaptor Protein, V-Crk Avian Sarcoma Virus CT10 Oncogene Homolog-Like, Crk-Like Protein
    Entrez ID:
    1399
    Related biomarkers:
    Expression
    Mutation
    Others
    2ms
    Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer. (PubMed, NPJ Precis Oncol)
    This is the largest study to investigate the distinct genomic landscape of CDH1-MT GC. Our data indicated GC patients with CDH1 mutations could potentially benefit from agents targeting PARP and Wee1.
    Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • ARID1A (AT-rich interaction domain 1A) • CDK12 (Cyclin dependent kinase 12) • APC (APC Regulator Of WNT Signaling Pathway) • CDH1 (Cadherin 1) • IGF1R (Insulin-like growth factor 1 receptor) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • WRN (WRN RecQ Like Helicase) • POT1 (Protection of telomeres 1) • FANCC (FA Complementation Group C)
    |
    TP53 mutation • HER-2 amplification • ARID1A mutation • CDK12 mutation • CDH1 mutation • WRN mutation • CRKL amplification • IGF1R amplification
    9ms
    Novel molecular subtypes of intracranial germ cell tumours expand therapeutic opportunities. (PubMed, Neuro Oncol)
    Novel genomic aberrations and molecular subtypes were identified in IGCTs. These findings provide molecular basis for the potential introduction of new treatment strategies in this setting.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein)
    |
    KRAS mutation • KRAS amplification • MTOR mutation • CRKL amplification
    11ms
    Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives. (PubMed, Virchows Arch)
    In conclusion, our study split the histological marker-null LCC into two different transcriptomic entities, with POU2F3, FOXI1, and AIM2 genes as differential expression markers that might be probed by immunohistochemistry for the differential diagnosis between Pure-LCC and ADLike-LCC. Finally, the identification of several signatures linked to replication stress in Pure-LCC and inflammasome complex in ADLike-LCC could be useful for designing new potential therapeutic approaches for these subtypes.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • POU2F3 (POU Class 2 Homeobox 3)
    |
    TP53 mutation • CRKL amplification
    almost2years
    Genetic alterations of GI-NECs involving three main signaling pathways. (PubMed, Cancer Med)
    Genetic alterations were very common in NECs and rare in NETs, and frequently involved three main signaling pathways. NEC patients harboring these genetic alterations may benefit from targeted therapy and PD-1/PD-L1 immunotherapy.
    Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RB1 (RB Transcriptional Corepressor 1) • mTOR (Mechanistic target of rapamycin kinase) • CCNE1 (Cyclin E1) • MCL1 (Myeloid cell leukemia 1) • SMAD4 (SMAD family member 4) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • TGFB1 (Transforming Growth Factor Beta 1) • DDR2 (Discoidin domain receptor 2)
    |
    TP53 mutation • CCNE1 amplification • MTOR mutation • CRKL amplification
    over2years
    Anatomic position determines oncogenic specificity in melanoma. (PubMed, Nature)
    Abrogation of this CRKL-driven programme eliminated the anatomic specificity of acral melanoma. These data suggest that the anatomic position of the cell of origin endows it with a unique transcriptional state that makes it susceptible to only certain oncogenic insults.
    Journal
    |
    BRAF (B-raf proto-oncogene) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein)
    |
    BRAF mutation • CRKL amplification
    over2years
    The genomic landscape of primary and secondary angiosarcomas, a rare heterogenous group of soft tissue sarcomas (AACR 2022)
    We showed a clear distinction in genomic profiles of AS subgroups with specific pathogenic alterations. Especially secondary AS may benefit from treatment with ICI based on frequent MYC amplifications, DDR mutations, and high TMB. These data show clear evidence for the development of future treatment strategies with targeted therapy and ICI for this rare heterogeneous group of STS.
    Late-breaking abstract • Tumor mutational burden
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • FLT4 (Fms-related tyrosine kinase 4) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit)
    |
    TP53 mutation • TMB-H • BRAF mutation • MYC amplification • CRKL amplification
    |
    TruSight Oncology 500 Assay